



TRANSFORMING HEALTHCARE

OUR INVESTMENT STRATEGY

In 2007, our partners saw an opportunity to build a different kind of venture capital firm – one that could fill a growing innovation gap by focusing squarely on launching exceptional companies in areas of disruptive science and medicine to make a difference in patients' lives. We discover, launch and build great companies based on bold ideas that meet at the intersection of science, strategy, business and medicine - where transformational science meets operational reality - providing the best opportunity to dramatically impact the lives of patients.



QUICK FACTS

- Year firm launched: 2007
- \$\$ under management: \$1.9 billion
- Number of portfolio companies: 44
- Number of clinical studies underway within the portfolio: 45+
- Number of diseases our companies are targeting: 60+

THE THIRD ROCK TEAM

Our team has a proven record of translating disruptive technologies into valuable business enterprises. We adhere to a "Third Rock Forever" philosophy, realizing that we have been phenomenally successful because of the contributions of the whole Third Rock team. People are our greatest asset, and we invest significant effort and resources to ensure we hire the best people at Third Rock and across the portfolio. Working closely with leading scientific and business visionaries as well as industry partners, our team is focused on identifying opportunities to change the future of medicine and rigorously vets those ideas through our discovery process to develop the vision, strategy and plan needed to succeed.

A FORMULA FOR INNOVATION

We only invest in the best of those ideas. We are actively involved in the early stages of our companies' development, typically serving as members of the founding management teams, to build a strong foundation, put in place the right people and culture, and set the companies on a path to scientific and operational excellence.

Then we build on that foundation, transitioning out of our interim leadership roles as we put in place rock star management teams. We bring to bear the vast experience, expertise and network of our team and across our portfolio to help our companies succeed. Management teams can tap into our network of experts across disciplines, including science, medicine, business, healthcare economics and regulatory strategy. Our partner development team leverages our relationships with decision-makers in pharma to support business development efforts across our portfolio. Our strategy team serves as an advisory resource around critical business development, financial and operational decisions. Our Beyond Great leadership program provides our portfolio leaders with a peer-to-peer network, as well as tools and resources focused on shared elements of building transformational companies. We build great companies together, with our portfolio leaders, scientific founders, advisors and industry partners.

OUR CORE VALUES



ATTITUDE

Nothing is impossible

PATIENTS

Making a difference through breakthroughs in medicine

+ PARTNERS

Make them raving fans

ORGANIZATION

Great people, great culture, great accomplishments

ENTREPRENEURS

Passionately innovate, found, build, have fun





DISCOVER. LAUNCH. BUILD.

We take a long-term approach to company building, creating a portfolio of companies with the potential to make a dramatic difference in patients' lives. Our unique Discover, Launch, Build process brings together the best inside and outside experts, allocates capital and resources based on where an idea or company is in its development and provides our companies with the support necessary to advance novel therapies, devices and diagnostics.

DISCOVER.





LAUNCH.



NEW COS

Series A

FOCUSED EXECUTION



ACTIVE COMPANY BUILD

BUILD.

DRIVING LIQUIDITY

We discover companies based on disruptive science & technology that will dramatically improve the lives of patients.

GROUP GENIUS

We launch companies with a solid foundation of science, medicine, business and strategy.

We build companies by developing a real-world road map to advance novel therapies, devices and diagnostics.

MAKING A DIFFERENCE FOR **PATIENTS**

We have built a portfolio of companies working on fundamentally new approaches to diagnose and treat fatal and debilitating diseases in patients in dire need of effective treatments. Many of those companies are pioneering potentially disruptive areas of science and medicine, including new modalities such as gene therapy and genome editing and emerging scientific fields such as cellular metabolism, neuromodulation and epigenetics. In nine years, our companies have brought five products to market and are conducting 45+ clinical trials targeting more than 60 diseases, for many of which there are no approved therapies.

THIRD ROCK PARTNERS

Alexis Borisy

Abbie Celniker, Ph.D.

Neil Exter

Kevin Gillis

Charles Homcy, M.D.

Sarah Larson

Mark Levin

Craig Muir

Cary Pfeffer, M.D.

Kevin Starr

Robert Tepper, M.D.

BOSTON

29 Newbury Street 3rd Floor Boston, MA 02116 P (617) 585-2000 F (617) 859-2891

SAN FRANCISCO

455 Mission Bay Blvd. South Suite 575 San Francisco, CA 94158 P (415) 766-3600 F (415) 766-3699

For more information about Third Rock. visit our website ThirdRockVentures.com or check us out on LinkedIn.in

To learn more about career opportunities within the firm and our portfolio companies, please visit ThirdRockVentures.com/Careers-Overview or email us at trytalent@ thirdrockventures.com.